Carisma Therapeutics (CARM) to Release Earnings on Monday

Posted by Amy Steele on Mar 25th, 2026

Carisma Therapeutics (NASDAQ:CARM – Get Free Report) is expected to issue its resultson Monday, March 30th. Analysts expect the company to announce earnings of ($0.1474) per share and revenue of $4.2290 million for the quarter.

Carisma Therapeutics Stock Down 8.3%

NASDAQ:CARM traded down $0.00 during trading hours on Wednesday, reaching $0.03. 61,089 shares of the company’s stock were exchanged, compared to its average volume of 113,026. The company has a market capitalization of $1.44 million, a P/E ratio of 0.05 and a beta of 1.86. Carisma Therapeutics has a 12 month low of $0.03 and a 12 month high of $1.27. The business’s 50-day simple moving average is $0.04 and its two-hundred day simple moving average is $0.09.

Hedge Funds Weigh In On Carisma Therapeutics

An institutional investor recently bought a new position in Carisma Therapeutics stock. Jane Street Group LLC bought a new position in shares of Carisma Therapeutics Inc. (NASDAQ:CARM – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 150,810 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned 0.36% of Carisma Therapeutics as of its most recent SEC filing. 44.27% of the stock is currently owned by institutional investors and hedge funds.

About Carisma Therapeutics

(Get Free Report)

Carisma Therapeutics, Inc is a clinical-stage biotechnology company headquartered in the United States that focuses on harnessing the innate immune system to treat cancer and inflammatory diseases. Through its proprietary CARMA (Chimeric Antigen Receptor Macrophage) platform, Carisma engineers macrophages and other myeloid cells to seek out, engulf and destroy diseased cells while reprogramming the surrounding microenvironment. This approach aims to address key limitations of existing T-cell therapies by leveraging the unique trafficking and immunomodulatory properties of innate immune cells.

The company’s lead oncology candidate, CT-0508, employs a HER2-targeted CAR expressed on macrophages to infiltrate and remodel HER2-positive solid tumors.